Teva Pharma (TEVA) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
RBC Capital Upgrades Teva Pharma (TEVA) to Outperform
November 3, 2014 8:09 AM ESTRBC Capital upgraded Teva Pharma (NYSE: TEVA) from Sector Perform to Outperform with a price target of $68.00.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $56.47 yesterday.
... MoreTeva Pharma (TEVA) Price Target Raised to $64 at Deutsche Bank
October 30, 2014 2:00 PM EDTDeutsche Bank maintained a Buy rating on Teva Pharma (NYSE: TEVA) and raised its price target to $64.00 (from $63.00). The change follows solid Q3 results.
Analyst Gregg Gilbert said, "We updated our model following TEVAs 3Q results, which were notable for significant... More
